Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, although Amazon.com made losses for many years after ...
Shareholders in DermTech, Inc. (NASDAQ:DMTK) had a terrible week, as shares crashed 31% to US$0.87 in the week since its latest yearly results. The results overall were pretty much dead in line with ...
DermTech Inc DMTK shares were soaring to a new high Thursday after the company unveiled a contract with Blue Cross Blue Shield of Texas for its melanoma gene express test. What Happened: La Jolla, ...
SAN DIEGO--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today reported its ...
DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today its support and presentation in the Melanoma Research ...
DermTech provides genomic analysis of skin samples collected non-invasively using our Smart Stickers™. DermTech markets and develops products that facilitate the early detection of skin cancers and is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback